Does lurbinectedin have immunomodulatory effects?

How lurbinectedin affects immune cells

Lurbinectedin binds DNA in the minor groove and blocks transcription, which rapidly reduces tumor-cell viability. In laboratory models, this DNA damage also triggers release of damage-associated molecular patterns that can recruit and activate dendritic cells and cytotoxic T cells, producing a measurable increase in CD8+ infiltration within treated tumors.

Can the drug turn a “cold” tumor “hot”?

Preclinical studies show that lurbinectedin increases expression of MHC class I and PD-L1 on cancer cells while lowering regulatory T-cell and myeloid-derived suppressor cell populations. These shifts convert some immunologically inert tumors into ones that respond better to PD-1 or PD-L1 checkpoint inhibitors in mouse models.

How long do the immune changes last?

In xenograft experiments, the rise in cytotoxic T-cell density peaks around day 7–10 after a single dose and declines once drug levels fall below the threshold needed to sustain DNA damage. Clinical pharmacokinetic data indicate that weekly dosing may be required to maintain the immunomodulatory window.

Does combining lurbinectedin with immunotherapy improve outcomes?

Ongoing phase 1/2 trials pair lurbinectedin with atezolizumab or pembrolizumab in small-cell lung cancer and sarcoma. Early read-outs report objective response rates roughly double those seen with lurbinectedin alone, but larger randomized studies are still needed to confirm a true synergistic benefit.

What side effects are linked to its immune activity?

Patients receiving lurbinectedin show higher rates of transient lymphopenia and fatigue than those on non-immunomodulatory chemotherapies. These effects are dose-dependent and usually reversible within two weeks after the last infusion.

When does patent protection end?

The composition-of-matter patent covering lurbinectedin expires in 2030 in the United States, with possible extensions. DrugPatentWatch.com lists both the basic patent and several formulation patents that could delay generic entry until the mid-2030s.